![Western Blot: TNF-alpha Antibody [NBP1-19532] - Recombinant human TNF alpha (10 ng) was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNF alpha in 5% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-Western-Blot-NBP1-19532-img0007.jpg "Western Blot: TNF-alpha Antibody [NBP1-19532] - Recombinant human TNF alpha (10 ng) was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNF alpha in 5% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
| Reactivity | Hu, Mu, Rt, Ca, Fi, Pm, Fe, Pm, PmSpecies Glossary |
| Applications | WB, Flow, ICC/IF, IHC, IHC |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | BSA Free |
| Concentration | 1.0 mg/ml |
| Immunogen | A synthetic peptide made to an internal portion of the human TNF alpha protein (between residues 100-200) [Uniprot: P01375] |
| Localization | Membrane |
| Predicted Species | Primate (100%), Monkey (98%), Feline (90%), Baboon (97%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | TNF |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Application Notes | Western Blot data from customer review and citation (PMID: 24223475). Use in Immunohistochemistry-free floating reported in scientific literature (PMID: 26219646). Use in Immunohistochemistry-Frozen reported in scientific literature (PMID: 26725948). Use in FLOW reported in scientific literature (PMID: 26889045). |
|
| Reviewed Applications |
|
|
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS |
| Preservative | 0.02% Sodium Azide |
| Concentration | 1.0 mg/ml |
| Purity | Immunogen affinity purified |
![Neutralization CXCL8/IL-8 Antibody (6217) [Unconjugated]](https://images.novusbio.com/images2/CXCL8_MAB208_Block_Neutralize_9064.jpg)
![Immunocytochemistry CXCL8/IL-8 Antibody (6217) [Unconjugated]](https://images.novusbio.com/images2/CXCL8_MAB208_Immunocytochemistry_9339.jpg)
![Western Blot CXCL8/IL-8 Antibody (6217) [Unconjugated]](https://images.novusbio.com/images2/mab208_human-il-8-cxcl8-mab-clone-6217-western-blot-1882021143847.jpg)
| Images | Ratings | Applications | Species | Date | Details | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
reviewed by:
Verified Customer |
Immunocytochemistry/Immunofluorescence | Rat | 10/13/2016 |
Summary
|
|||||||
Enlarge |
reviewed by:
Verified Customer |
IF | Other | 01/07/2016 |
Summary
|
||||||
-(01-mg)_NBP1-19532_8991.jpg)
Enlarge |
reviewed by:
Ranveer Singh |
WB | Human | 07/24/2014 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for TNF-alpha Antibody (NBP1-19532)Find related products by research area.
|
|
Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach... Read full blog post. |
|
Tired T cells: Hypoxia Drives T cell Exhaustion in the Tumor Microenvironment By Hunter MartinezThe paradigm shifting view of the immune system being leveraged to target cancer has led to numerous therapeutic breakthroughs. One major cell group responsible for this revelation is a T cell. ... Read full blog post. |
|
Immune Cell Metabolic Flux Influences Type I Diabetes By Hunter MartinezWhat is Immunometabolism?It is well established that abnormal metabolic environments can be a risk factor for disease development. One characteristic example is the role of dyslipidemia (high lev... Read full blog post. |
|
Read full blog post. |
|
Read full blog post. |
|
Read full blog post. |
|
Liver ASK1 activates autophagy to protect against hepatic fat accumulation, non-alcoholic steatohepatitis and fibrosis By Jamshed Arslan, Pharm. D., PhD. The most common chronic liver disorder worldwide is non-alcoholic fatty liver disease (NAFLD). This obesity-linked disorder can manifest as hepatic fat accumulation (steatosis) wit... Read full blog post. |
|
Metabolic Syndrome: Symptoms and associated disease states By Jamshed Arslan, Pharm. D., PhD. What is metabolic syndrome?It was 1988 when, after decades of research, Dr. GM Reaven of the Stanford University, CA, explained the relationship between four diseases:... Read full blog post. |
|
Increased wild type FUS levels in ALS patients lead to a toxic microenvironment and motor neuron neurodegeneration By Michalina Hanzel, PhDFUS mutations in Amyotrophic Lateral SclerosisFused in sarcoma (FUS) is a ribonucleoprotein that continuously shuttles between the nucleus and the cytoplasm to regulate pre-mRNA splicing, mRN... Read full blog post. |
|
You complete me: Natural killer cells need TGF-beta inhibition to effectively combat cancers By Jamshed Arslan Pharm.D. Natural killer (NK) cells are lymphocytes of the innate immune system that were first discovered for their “natural” ability to kill cancer cells. To use NK cells as anti-cancer therapy, t... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
5 | |
4 | |
3 | |
2 | |
1 |
| Verified Customer 10/13/2016 |
||
| Application: | Immunocytochemistry/Immunofluorescence | |
| Species: | Rat |
| Verified Customer 01/07/2016 |
||
| Application: | IF | |
| Species: | Other |
| Ranveer Singh 07/24/2014 |
||
| Application: | WB | |
| Species: | Human |
![Western Blot: TNF-alpha Antibody [NBP1-19532] - Scutellarin attenuates hypertension-induced brain expression of NF-kappaB, TNF-alpha, IL-1beta, and IL-18. Western immunoblot analysis for TNF-alpha in the rat cortex and striatum. Treatment with scutellarin significantly reduced the expression of these inflammatory markers in a dose-dependent manner. *P < 0.001 versus sham group; #P < 0.05, P < 0.001 versus NS group; &P < 0.001 versus low-dose group. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/mi/2013/432623/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-Western-Blot-NBP1-19532-img0008.jpg "Western Blot: TNF-alpha Antibody [NBP1-19532] - Scutellarin attenuates hypertension-induced brain expression of NF-kappaB, TNF-alpha, IL-1beta, and IL-18. Western immunoblot analysis for TNF-alpha in the rat cortex and striatum. Treatment with scutellarin significantly reduced the expression of these inflammatory markers in a dose-dependent manner. *P < 0.001 versus sham group; #P < 0.05, P < 0.001 versus NS group; &P < 0.001 versus low-dose group. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/mi/2013/432623/), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: TNF-alpha Antibody [NBP1-19532] - Analysis of a FFPE tissue section of mouse intestine using TNF-alpha antibody (NBP1-19532) at 1:300 dilution. The binding of this primary antibody to TNF-alpha protein in the section was detected using HRP-labeled secondary antibody and DAB reagent, and nuclei of cells were counterstained using hematoxylin. This TNF-alpha antibody generated an expected diffused immunostaining of this protein in the tested tissue. Staining was primarily observed in the epithelial cells and some cells showed membrane positivity also.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-Immunohistochemistry-Paraffin-NBP1-19532-img0005.jpg "Immunohistochemistry-Paraffin: TNF-alpha Antibody [NBP1-19532] - Analysis of a FFPE tissue section of mouse intestine using TNF-alpha antibody (NBP1-19532) at 1:300 dilution. The binding of this primary antibody to TNF-alpha protein in the section was detected using HRP-labeled secondary antibody and DAB reagent, and nuclei of cells were counterstained using hematoxylin. This TNF-alpha antibody generated an expected diffused immunostaining of this protein in the tested tissue. Staining was primarily observed in the epithelial cells and some cells showed membrane positivity also.")
![Immunohistochemistry-Paraffin: TNF-alpha Antibody [NBP1-19532] - Analysis of a FFPE tissue section of mouse intestine using TNF-alpha antibody (NBP1-19532) at 1:300 dilution. The binding of this primary antibody to TNF-alpha protein in the section was detected using HRP-labeled secondary antibody and DAB reagent, and nuclei of cells were counterstained using hematoxylin. This TNF-alpha antibody generated an expected immunopositivity of this protein in the tested tissue. Staining was primarily observed in the epithelial cells while some staining was present in mucosa muscularis also.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-Immunohistochemistry-Paraffin-NBP1-19532-img0006.jpg "Immunohistochemistry-Paraffin: TNF-alpha Antibody [NBP1-19532] - Analysis of a FFPE tissue section of mouse intestine using TNF-alpha antibody (NBP1-19532) at 1:300 dilution. The binding of this primary antibody to TNF-alpha protein in the section was detected using HRP-labeled secondary antibody and DAB reagent, and nuclei of cells were counterstained using hematoxylin. This TNF-alpha antibody generated an expected immunopositivity of this protein in the tested tissue. Staining was primarily observed in the epithelial cells while some staining was present in mucosa muscularis also.")
![Immunocytochemistry/ Immunofluorescence: TNF-alpha Antibody - BSA Free [NBP1-19532] - Effects of femoral artery occlusion on TNF-alpha signal in sensory nerves. (A) Seventy-two hours of femoral artery occlusion increased the levels of TNF-alpha in the DRG tissues as compared with them in DRG of control limbs (n = 6 in each group); & PTX given into the hindlimb muscles attenuated amplification of TNF-alpha in the DRG tissues of limbs with femoral artery occlusion (n = 8). ∗P < 0.05, occlusion group vs. control & occlusion with prior PTX. (B) Immunofluorescence was used to examine double-labeling for TNF-alpha & peripherin/NF-200 (n = 3). Peripherin was used to label DRG neurons that project thin C-fibers. NF200 was used to identify A-fibers of DRG neurons. Representative photomicrographs show co-existence of TNF-alpha & peripherin staining in DRG neurons (top panel), whereas few TNF-alpha & NF-200 staining were observed in DRG neurons (bottom panel). Arrows indicate representative positive cells for both TNF-alpha & peripherin after they were merged. Scale bar = 50 μm. (C) Representative bands (left panel) & averaged data (right panel), demonstrating that femoral artery occlusion upregulated protein expression TNF-alpha receptor subtype TNFR1, but not TNFR2. A significant difference in TNFR1 was seen between control & occluded groups. ∗P < 0.05 vs. control. n = 6 in each group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30374312), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-19532_rabbit-polyclonal-tnf-alpha-antibody-31020241618927.jpg "Immunocytochemistry/ Immunofluorescence: TNF-alpha Antibody - BSA Free [NBP1-19532] - Effects of femoral artery occlusion on TNF-alpha signal in sensory nerves. (A) Seventy-two hours of femoral artery occlusion increased the levels of TNF-alpha in the DRG tissues as compared with them in DRG of control limbs (n = 6 in each group); & PTX given into the hindlimb muscles attenuated amplification of TNF-alpha in the DRG tissues of limbs with femoral artery occlusion (n = 8). ∗P < 0.05, occlusion group vs. control & occlusion with prior PTX. (B) Immunofluorescence was used to examine double-labeling for TNF-alpha & peripherin/NF-200 (n = 3). Peripherin was used to label DRG neurons that project thin C-fibers. NF200 was used to identify A-fibers of DRG neurons. Representative photomicrographs show co-existence of TNF-alpha & peripherin staining in DRG neurons (top panel), whereas few TNF-alpha & NF-200 staining were observed in DRG neurons (bottom panel). Arrows indicate representative positive cells for both TNF-alpha & peripherin after they were merged. Scale bar = 50 μm. (C) Representative bands (left panel) & averaged data (right panel), demonstrating that femoral artery occlusion upregulated protein expression TNF-alpha receptor subtype TNFR1, but not TNFR2. A significant difference in TNFR1 was seen between control & occluded groups. ∗P < 0.05 vs. control. n = 6 in each group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30374312), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry/ Immunofluorescence: TNF-alpha Antibody - BSA Free [NBP1-19532] - Immunoflorescence staining results of TNF-alpha (96 h). A). Lamella of gill tissue (arrow). Control group. IF. 20 μm. B) Positive reaction in lamellar cells of gill tissue (arrows). Low dose toxic group. IF. 20 μm. C) Positivity in lamellar cells of gill tissue (arrow). High dose toxic group. IF. 20 μm. D) Liver tissue, vena centralis (arrow). Control group. IF. 20 μm. E) Positive reactions in hepatocytes (arrows). Low dose toxic group. IF. 20 μm. F) Positive reactions in hepatocytes (arrows). High dose toxic group. IF. 20 μm. G) Weak positive reactions in neurons (arrows). Control group. IF. 20 μm. H) Weak positivity in neurons (arrows). Low dose toxic group. IF. 20 μm. I) Positivity in neurons (arrows). High dose toxic group. IF. 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29321977), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-19532_rabbit-polyclonal-tnf-alpha-antibody-310202416171446.jpg "Immunocytochemistry/ Immunofluorescence: TNF-alpha Antibody - BSA Free [NBP1-19532] - Immunoflorescence staining results of TNF-alpha (96 h). A). Lamella of gill tissue (arrow). Control group. IF. 20 μm. B) Positive reaction in lamellar cells of gill tissue (arrows). Low dose toxic group. IF. 20 μm. C) Positivity in lamellar cells of gill tissue (arrow). High dose toxic group. IF. 20 μm. D) Liver tissue, vena centralis (arrow). Control group. IF. 20 μm. E) Positive reactions in hepatocytes (arrows). Low dose toxic group. IF. 20 μm. F) Positive reactions in hepatocytes (arrows). High dose toxic group. IF. 20 μm. G) Weak positive reactions in neurons (arrows). Control group. IF. 20 μm. H) Weak positivity in neurons (arrows). Low dose toxic group. IF. 20 μm. I) Positivity in neurons (arrows). High dose toxic group. IF. 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29321977), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/DATA_IL6_M6000_ELISA_936.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/IL-6_M6000_ELISA_415.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images/m6000b_mouse-il-6-quantikine-elisa-kit-44202415433118.jpg)
![N/A IL-10 [Biotin]](https://images.novusbio.com/images2/DATA_IL10_DY417_ELISA_2014.jpg)
![Bioactivity IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFNgamma_285IF_2848.jpg)
![SDS-PAGE IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFN-gamma_285-IF_230.jpg)
![SEC-MALS IFN-gamma [Unconjugated]](https://images.novusbio.com/images/285-if_recombinant-human-ifn-gamma-protein-sec-mals-1520239228..jpg)
![SDS-PAGE IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images2/IL-1_beta_201-LB_304.jpg)
![Bioactivity IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images2/IL-1_beta_201-LB_306.jpg)
![SEC-MALS IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images/201-lb_recombinant-human-il-1-beta-il-1f2-protein-sec-mals-123202491556.jpg)
![Bioactivity IL-2 [Unconjugated]](https://images.novusbio.com/images/202-il_recombinant-human-il-2-protein-bioactivity-174202314946.jpg)
![Bioactivity IL-4 [Unconjugated]](https://images.novusbio.com/images/protein/6507-ilcf_recombinant-human-il-4-cho-expressed-protein-cf-bioactivity-272020133214.jpg)
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![N/A C-Reactive Protein/CRP [Biotin]](https://images.novusbio.com/images2/DATA_CReactive_Protein_DY1707_ELISA_1701.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](https://images.novusbio.com/images2/CCL2_DCP00_ELISA_67.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](https://images.novusbio.com/images2/DATA_CCL2_DCP00_ELISA_633.jpg)
![N/A CCL2/JE/MCP-1 [HRP]](https://images.novusbio.com/images2/DATA_CCL2_DCP00_ELISA_634.jpg)
![SDS-PAGE Lymphotoxin-alpha/TNF-beta [Unconjugated]](https://images.novusbio.com/images2/Lymphotoxin-alpha_211-TBB_CF_695.jpg)
![Bioactivity Lymphotoxin-alpha/TNF-beta [Unconjugated]](https://images.novusbio.com/images2/Lymphotoxin-alpha_211-TBB_CF_697.jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/DATA_TNF_RI_DRT100_ELISA_815.jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/DATA_TNF_RI_DRT100_ELISA_816.jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/TNF_RI_DRT100_ELISA_175.jpg)
![Western Blot ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Western_Blot_5097.jpg)
![Immunohistochemistry ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Immunohistochemistry_20696.jpg)
![Knockout Validated ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Knockout_Validated_22864.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")
-(01-mg)_NBP1-19532_8991.jpg)